In her presentation at Fall Clinical NP/PA, Heather Gates, PA-C, shared how professionals can enhance their practice using AI and social media, fostering authenticity and patient trust in a digital age.

Lauren Miller, PA-C, MPAS, highlights the vital role of mentorship in dermatology, emphasizing its impact on professional growth and patient care at the Fall Clinical conference.

Jamie Restivo, PA-C, a board-certified dermatology physician assistant and current president of the Pennsylvania Dermatology Physician Assistants (PDPA), gave insights into the PA perspective.

Explore the latest insights in dermatology at the Fall Clinical PA/NP Conference, featuring experts like James Del Rosso, DO, and networking opportunities for PA NPs.

Discover expert insights and practice management tips at the Fall Clinical PA/NP Conference in Orlando, featuring top dermatology professionals.

Jonathan Silverberg, MD, PhD, MPH, talks about when and how to take itch into consideration when choosing a therapy for AD.

RAPIDS 2025 captivated with expert insights on immuno-dermatology, featuring engaging sessions and lively panels.

Jonathan Silverberg, MD, PhD, MPH, shares pearls from the ADvocate1 and 2 trials examining the use of lebrikizumab for AD.

Jonathan Silverberg, MD, PhD, MPH, talks about therapies used for AD, including nemolizumab.

Researchers reveal the resilience of Cutibacterium acnes in the skin microbiome post-laser treatments, suggesting its beneficial roles in skin health and aging.

A new study highlights the significant long-term improvements in lesions and scarring of a clindamycin phosphate 1.2%, adapalene 0.15%, and benzoyl peroxide 3.1% formulation.

Recent posters at SID revealed significant increases in psoriasis and cellulitis cases in the US, highlighting urgent needs for prevention and treatment strategies.

Thiamidol emerges as a promising treatment for hyperpigmentation, showcasing superior efficacy and safety compared to traditional options like hydroquinone.

GLP-1 receptor agonists show promise in reducing cardiovascular risks for patients with chronic inflammatory skin diseases like psoriasis and atopic dermatitis.

Biologics significantly lower cardiovascular risks in psoriasis patients on statins, highlighting their dual benefits for skin and heart health.

Scott Batty, MD, and Chris VanDeusen, PhD, provided insights on AX-158's phase 2a results, presented at the SID Annual Meeting.

Discover the promising results of risankizumab for treating genital and scalp psoriasis, showcasing significant improvements in symptoms and quality of life.

Recludix Pharma unveils a groundbreaking BTK SH2 inhibitor, showcasing superior selectivity and efficacy for chronic spontaneous urticaria treatment at SID 2025.

Extended oral corticosteroid therapy in patients with atopic dermatitis significantly increases cardiovascular and thrombotic risks, urging careful treatment evaluations.

Researchers reveal TRIV-509, a novel monoclonal antibody, shows promise in rapidly improving atopic dermatitis by restoring skin barrier integrity and reducing inflammation.